New diabetes shot SHR-3167 enters early human testing
NCT ID NCT07032688
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests a new injectable drug called SHR-3167 in 55 adults with type 2 diabetes. The study measures how the drug moves through the body and how well it controls blood sugar. Participants will receive either SHR-3167 or insulin degludec to compare their effects and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-3167 injection
- What this could lead to
- If successful, this could lead to a new once-daily insulin-like option for managing type 2 diabetes.
- What could go wrong
- This is an early Phase 1 study with only 55 people, so safety and effectiveness are not yet proven. The drug may cause hypoglycemia or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?